6 completed, 2 terminated, 1 not yet recruiting, 1 recruiting. 11 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 6, Terminated 2, Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
Follow Malignant Melanoma Stage IV: new trials by email Literature Review of Malignant Melanoma Stage IV trials Research Report on Malignant Melanoma Stage IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy - Malignant Melanoma With Metastasis, Malignant Melanoma | Phase 2 | Not yet recruiting | Rapa Therapeutics LLC | 65 | 2027-03-01 | 2026-03-19 |
| [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer [68Ga]Ga-FAPI-46 - Malignant Melanoma Stage IV | Phase 2 | Recruiting | Barbara Malene Fischer | 20 | 2025-08-15 | 2025-10-10 |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma Pembrolizumab, Encorafenib, Binimetinib - Malignant Melanoma, Metastatic Melanoma | Phase 2 | Completed | Dr. Ronnie Shapira | 1 | 2023-09-05 | 2025-07-22 |
| Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases Vemurafenib, Cobimetinib - Malignant Melanoma Stage IV, BRAF V600 Mutation | Phase 2 | Terminated | Technische Universität Dresden | 20 | 2018-07-01 | 2023-09-14 |
| Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients Fludarabine, Cyclophosphamide, TIL - Malignant Melanoma Stage IV | Phase 2 | Unknown | Sheba Medical Center | 30 | 2017-06-05 | 2023-01-26 |
| Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib Fotemustine + Vemurafenib - Malignant Melanoma Stage IV | Phase 2 | Completed | Paola Queirolo | 31 | 2013-02-01 | 2016-01-20 |
| mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma Dendritic cell therapy - Malignant Melanoma Stage III, Malignant Melanoma Stage IV | Phase 2 | Completed | Universitair Ziekenhuis Brussel | 88 | 2012-10-01 | 2017-05-24 |
| Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma TriMix-DC and ipilimumab - Malignant Melanoma Stage III, Malignant Melanoma Stage IV | Phase 2 | Completed | Bart Neyns | 39 | 2011-02-01 | 2021-03-29 |
| IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma IL15-DC Vaccine - Malignant Melanoma Stage III, Malignant Melanoma Stage IV | Phase 1 / Phase 2 | Completed | Baylor Research Institute | 20 | 2011-01-01 | 2016-12-22 |
| Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients DC Vaccine & Cyclophosphamide, DC Vaccine & Placebo - Malignant Melanoma Stage IV | Phase 2 | Terminated | Baylor Research Institute | 9 | 2008-06-01 | 2013-07-08 |
| Combined Modality Treatment for Patients With Stage IV Melanoma DC Vaccine and Cyclophosphamide - Malignant Melanoma Stage IV | Phase 1 / Phase 2 | Completed | Baylor Research Institute | 41 | 2006-03-01 | 2013-06-13 |
Melanoma (11) · Brain Neoplasms (1) · Neoplasms (1)
Neoplasms by Histologic Type (11) · Neoplasms by Site (11) · Neoplasms, Germ Cell and Embryonal (11) · Neoplasms, Nerve Tissue (11) · Neuroectodermal Tumors (11) · Neuroendocrine Tumors (11) · Nevi and Melanomas (11) · Skin Diseases (11) · Skin Neoplasms (11) · Skin and Connective Tissue Diseases (11) · Neoplasms (10) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Nervous System Diseases (1)
Cyclophosphamide (3) · Ipilimumab (2) · Vemurafenib (2) · FMT protocol (1) · Interleukin-2 (1) · Nivolumab (1) · binimetinib (1) · cobimetinib (1) · encorafenib (1) · fludarabine (1) · fotemustine (1) · pembrolizumab (1)
Baylor Research Institute (3) · Barbara Malene Fischer (1) · Bart Neyns (1) · Dr. Ronnie Shapira (1) · Paola Queirolo (1) · Rapa Therapeutics LLC (1) · Sheba Medical Center (1) · Technische Universität Dresden (1) · Universitair Ziekenhuis Brussel (1)
United States (4) · Belgium (2) · Israel (2) · Denmark (1) · Germany (1) · Italy (1)
Anna Karolina Palucka, MD, PhD (1) · Bart Neyns, Phd Md (1) · Daniel Fowler, M.D. (1) · Friedegund Meier, MD (1) · Joseph Fay, M.D. (1) · Joseph Fay, MD (1) · Joseph W. Fay, MD (1) · Paola Queirolo, MD (1) · Ronnie Shapira-Frommer, Dr (1)
PMID 29552321, PMID 32114500, PMID 33990415
2017 (1), 2023 (1), R01CA140602 (1)